| Ytd | 3.23% | |
| 1y | -29.67% |
| Open | 1.32 | Prev Close | 1.33 | Low | 1.27 | High | 1.33 | Mkt Cap | 79.13M |
| Vol | 146.72K | Avg Vol | 1.14M | EPS | -1.59 | P/E | -0.84 | Forward P/E | -1.21 |
| Beta | -0.31 | Short Ratio | 12.98 | Inst. Own | 64.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 1.32 | 200-d Avg | 1.39 | 1yr Est | 40.56 |
BMEA News
•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservati
Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on P
SAN CARLOS, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion
SAN CARLOS, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion
Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinic
SAN CARLOS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Cit
Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type
SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusi
Biomea Fusion, Inc. (NASDAQ: BMEA - Get Free Report) has been given a consensus rating of "Moderate
COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II en
Biomea Fusion, Inc. (BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabete
Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Anta
SAN CARLOS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusi
Biomea Fusion (NASDAQ: BMEA - Get Free Report) is anticipated to announce its Q4 2025 results before
Biomea Fusion (NASDAQ: BMEA) shares rose Friday after the company reported positive Phase II data fo
SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion
SAN CARLOS, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Company” or
Biomea Fusion (NASDAQ: BMEA) highlighted two clinical-stage programs focused on diabetes and obesity
Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Gainers
On Friday, 431 companies hit new 52-week lows.
On Monday, 147 stocks hit new 52-week lows.
On Thursday, 112 stocks made new 52-week lows.
On Thursday, 147 companies achieved new lows for the year.